Compare SABS & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | ARL |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 233.9M |
| IPO Year | N/A | 1999 |
| Metric | SABS | ARL |
|---|---|---|
| Price | $3.85 | $14.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 996.7K | 2.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 206.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,014,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.70 |
| 52 Week Low | $1.60 | $12.42 |
| 52 Week High | $6.60 | $20.00 |
| Indicator | SABS | ARL |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 56.25 |
| Support Level | $3.54 | $12.64 |
| Resistance Level | $4.11 | $16.76 |
| Average True Range (ATR) | 0.35 | 0.52 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 37.74 | 83.32 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.